Infinity is clinical-stage biopharmaceutical company focused on developing new medicines for the treatment of certain cancers.
We are advancing IPI-549, an investigational immuno-oncology development candidate for the treatment of solid tumors.
Our team of passionate and committed individuals has expertise in all areas of our business. We are continuously looking for new, efficient approaches to how we operate. We have a passionate innovation for everything we do. This belief that “the failure to try is worse than failure in trying” is just one of our values that forms the foundation of how we work together as a community with the shared goal of bringing important new medicines to patients.